FORAGER-2 study

The purpose of this study is to better understand how individuals with metastatic urothelial carcinoma that contains an FGFR3 genetic alteration may respond to treatment with a combination of Vepugratinib, Enfortumab vedotin, and Pembrolizumab. FGFR3 alterations can influence how bladder cancer grows and spreads, which may affect treatment options and overall disease behavior. Researchers aim to explore how these therapies influence tumor behavior, treatment tolerance, disease progression, and how FGFR3‑altered cancers respond to emerging treatment strategies.

 

Disclaimer: This summary is for informational purposes only. It does not invite participation, offer medical advice, or suggest that any investigational medication is safe, effective, or approved. Individuals with urothelial carcinoma should consult their healthcare provider for guidance.